Aquestive Therapeutics (AQST) Share-based Compensation (2018 - 2026)

Aquestive Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 229.73% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $9.2 million, a 914.16% increase from a year earlier, with the FY2025 full-year figure at $7.6 million, up 592.46% from the prior year.
• Share-based Compensation retreated to $2.3 million in Q1 2026 per AQST's latest filing, from $6.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $6.8 million in Q4 2025 and bottomed at -$3.6 million in Q4 2024.
• The 5-year median for Share-based Compensation is $833500.0 (2023), against an average of $981071.4.
• Across the five-year window, Share-based Compensation plunged 482.45% in 2024 and jumped 55260.0% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $3000.0 in 2022, then jumped by 31233.33% to $940000.0 in 2023, then plunged by 482.45% to -$3.6 million in 2024, then jumped by 290.04% to $6.8 million in 2025, then slumped by 66.07% to $2.3 million in 2026.
• Per Business Quant, the three latest AQST Share-based Compensation figures stand at $2.3 million (Q1 2026), $6.8 million (Q4 2025), and -$2.7 million (Q3 2025).